Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.

Zerion Pharma A/S


Zerion Pharma is a pharmaceutical company aspiring to transform the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. 

The company was established in 2019 as a spinout from the University of Copenhagen based on a decade of research. Zerion Pharma has pioneered the Dispersome® technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic options for patients.

The Dispersome® technology is based around a class of novel excipient, namely beta-lactoglobulin (BLG), to formulate poorly soluble small molecule drugs into stable amorphous drug delivery systems with a high drug load. By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability and therapeutic outcomes and reducing adverse effects in patients. The Dispersome® technology is well accepted with no safety risks and is compatible with standard solid oral dosage form manufacturing.

Zerion Pharma A/S develops proprietary drug formulations and offers the Dispersome® technology to established pharma companies as a means to solve their most challenging drug solubility problems. Through the use of our proprietary Dispersome® formulation platform, we aim to develop new treatment options for patients across all small molecule therapy areas and strive to improve the lives of patients around the world. 

Se allaNyheter

Fakta om Zerion Pharma A/S

Zerion Pharma A/S
Fruebjergvej 3
2100 Copenhagen

Rudersdal Kommune

VAT nummer: DK40169229


Ieva Jasiukenaite

Sänd till en kollega